Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
Expanded eligibility now includes weight loss (beyond diabetes), opening doors for more people to pursue supervised GLP-1 therapy
As an elective wellness service, MIC Plus B12 is not intended to diagnose or treat any medical condition
This may have limited our statistical power to detect smaller effects, increasing the risk of type II error in those specific subanalyses
Yucca Health is a telehealth platform that connects patients with licensed medical providers and partner pharmacies for GLP-1 weight loss programs
Zalecenia kliniczne dotyczce postpowania u chorych na cukrzyc 2022, Stanowisko Polskiego Towarzystwa Diabetologicznego